Understanding the mechanisms by which eosinophils migrate into and across the intestinal epithelium can provide alternative therapeutic targets for conditions characterized by eosinophilic cryptitis and crypt abscesses. Eosinophil migration is dependent on adhesion molecules such as selectins. Human eosinophils express L-selectin and P-selectin counterligand P-selectin glycoprotein ligand-1 (PSGL-1). The tetrasaccharide sialyl Lewis x (sLe x ) binds to all three selectins, so compounds that mimic sLe x , such as TBC1269, are potential antagonists. We hypothesized that eosinophils migrate from the basolateral to the apical surface of intestinal epithelium through the orchestrated effects of selectins. TBC1269 was added to fluorescently labeled HL-60 clone 15 eosinophils as well as human blood eosinophils, in incremental amounts. Subsequently, blocking antibodies toward L-selectin and PSGL-1 were used in a similar manner. HL-60 eosinophils were allowed to migrate into T-84 monolayers. The number of migrated HL-60 cells was calculated by comparing fluorescence with known cell densities. HL-60 and human eosinophils that were undergoing migration were significantly lower in the presence of TBC1269. This effect was concentration dependent, and near complete inhibition of migration was seen at a TBC1269 concentration of 10 mg/mL. In addition, HL-60 eosinophil migration was significantly lower in the presence of the blocking antibodies to PSGL-1 and L-selectin (39.2 and 51.6% inhibition, respectively). Simultaneous blocking of PSGL-1 and L-selectin resulted in inhibition of 76.0% of the migration. The results of this study suggest a major role for selectins in the intestinal epithelial migration of differentiated eosinophils. sLe x , Lselectin, and the P-selectin counterligand PSGL-1 can be potential therapeutic targets. The gastrointestinal tract represents the largest reservoir of eosinophils within the body. In the gut, eosinophils play an important role in several inflammatory disorders (1). During these conditions, the eosinophils migrate into the intestinal lumen, forming eosinophilic crypt abscesses (2). Eosinophil products then are released, which can contribute to epithelial damage (3).
Understanding the mechanisms by which eosinophils migrate into and across the intestinal epithelium can provide alternative therapeutic targets for conditions characterized by eosinophilic cryptitis and crypt abscesses. Eosinophil migration is dependent on adhesion molecules such as selectins. Human eosinophils express L-selectin and P-selectin counterligand P-selectin glycoprotein ligand-1 (PSGL-1). The tetrasaccharide sialyl Lewis x (sLe x ) binds to all three selectins, so compounds that mimic sLe x , such as TBC1269, are potential antagonists. We hypothesized that eosinophils migrate from the basolateral to the apical surface of intestinal epithelium through the orchestrated effects of selectins. TBC1269 was added to fluorescently labeled HL-60 clone 15 eosinophils as well as human blood eosinophils, in incremental amounts. Subsequently, blocking antibodies toward L-selectin and PSGL-1 were used in a similar manner. HL-60 eosinophils were allowed to migrate into T-84 monolayers. The number of migrated HL-60 cells was calculated by comparing fluorescence with known cell densities. HL-60 and human eosinophils that were undergoing migration were significantly lower in the presence of TBC1269. This effect was concentration dependent, and near complete inhibition of migration was seen at a TBC1269 concentration of 10 mg/mL. In addition, HL-60 eosinophil migration was significantly lower in the presence of the blocking antibodies to PSGL-1 and L-selectin (39.2 and 51.6% inhibition, respectively). Simultaneous blocking of PSGL-1 and L-selectin resulted in inhibition of 76.0% of the migration. The results of this study suggest a major role for selectins in the intestinal epithelial migration of differentiated eosinophils. sLe x , Lselectin, and the P-selectin counterligand PSGL-1 can be potential therapeutic targets. The gastrointestinal tract represents the largest reservoir of eosinophils within the body. In the gut, eosinophils play an important role in several inflammatory disorders (1) . During these conditions, the eosinophils migrate into the intestinal lumen, forming eosinophilic crypt abscesses (2) . Eosinophil products then are released, which can contribute to epithelial damage (3) .
The infiltration of the leukocytes to the areas of injury and inflammation is accomplished by the coordinated actions of cellular adhesion molecules under the direction of chemokine signaling. Three families of adhesion molecules contribute to eosinophil migration: selectins, integrins, and immunoglobulins. The family of selectins consists of three members: L-, P-, and E-selectins. The interaction between the selectins and their ligands is carbohydrate based. Therefore, compounds such as the tetrasaccharide sialyl Lewis x (sLe x ) are known to bind to all selectins, acting as an antagonist (4) .
The process of eosinophil migration across the endothelium has been widely investigated, yet little is known about eosinophil-epithelial interactions in the gut. Measures that can prevent eosinophil recruitment into the intestinal epithelium are likely to have therapeutic value. Primary molecular targets for prevention of eosinophil accumulation are the adhesion molecules that mediate leukocyte interactions with vascular endothelium and extracellular matrix proteins.
However, studies of eosinophil function are hindered by the relative paucity of eosinophils in the circulation and the difficulty in purification from neutrophils. Furthermore, eosinophils that are isolated from different individuals may respond differently to identical conditions. Thus, HL-60 -differentiated eosinophils present a considerable advantage in large-scale studies for eosinophil chemotaxis. Previous studies in our laboratory demonstrated that HL-60 clone 15 cells function as a viable model for the study of eosinophil migration across intestinal epithelial monolayers (5).
We hypothesized that eosinophils migrate from the basolateral to the apical surface of intestinal epithelium through the orchestrated effects of selectins. This study examined the inhibitory effect of sLe x mimetic on the intestinal epithelial migration of HL-60 -differentiated eosinophils, as well as human peripheral eosinophils. Consequently, the role of individual selectins during the process of migration was evaluated. The results of this study suggest a major role for selectins in the intestinal epithelial migration of differentiated eosinophils. other investigators have shown, the cell viability was Ͼ98% when assessed by 0.2% trypan blue dye exclusion. To assess purity of eosinophilic differentiation, cells were stained with Luxol fast blue. As with other reported experience, cell purity was Ͼ90% (6,7).
METHODS
Preparation of monolayers. T-84 cells (ATCC) were maintained in DMEM/F12 (Life Technologies), fetal bovine serum (Atlanta Biologicals, Atlanta, GA), penicillin, streptomycin, and amphotericin (Life Technologies) in a humidified atmosphere with 5% CO 2 . Approximately 100 ϫ 10 3 cells were plated on the undersurface of each fluoroblock cell culture insert as previously described (5) TBC1269 and fMLP-induced HL-60 migration. fMLP was added to the apical bathing solution at a concentration of 1 M to determine its effect on the migration of HL-60 eosinophils. Migration was determined as described above. TBC1269 (Texas Biotechnology, Houston, TX), which is a sLe x mimetic with structural similarities to sialyl dimeric-Lewis x that has been shown to inhibit selectins and their ligands resulting in the inhibition of the adhesion of leukocytes and their recruitment to sites of injury in vivo and in vitro (8, 9) , was added to HL-60 clone 15 cells in incremental amounts for 30 min before migration. Migration was allowed to proceed and was quantified as described above.
L-selectin and P-selectin glycoprotein ligand-1 blockade and fMLPinduced HL-60 eosinophil migration. To determine the role of individual selectins and their ligands, blocking antibodies were used. The blocking antibodies were targeted against the selectins and the selectin ligands, which are known to be expressed by eosinophils, namely L-selectin and the P-selectin glycoprotein ligand-1 (PSGL-1). Blocking antibodies at 1-10 g/mL (6.7-67 nM) and 50 -100 g/mL (13.5-27 nM), respectively, were allowed to incubate with the HL-60 cells for 30 min before the migration experiment. Such concentration of the blocking antibodies is similar to those used in previously published reports (10) . Migration then was allowed to proceed as described above.
Effect of TBC1269 on the intestinal epithelial migration of human peripheral eosinophils. Human peripheral eosinophils were used to validate the migration experiments performed with the HL-60 eosinophils. Briefly,
Eosinophils were isolated by centrifuging dextran-sedimented leukocytes on Ficoll-Histopaque (Sigma Chemical Co.). The leukocytes that were isolated were washed in PBS without calcium or magnesium. The eosinophils were purified from the neutrophils by immunomagnetic removal (MACS system; Miltinyi Biotec Systems, Auburn, CA) of CD16-positive cells (neutrophils). The isolated human eosinophils have a viability and purity Ͼ95%. The pan-selectin antagonist, TBC1269, was added in incremental amounts to the eosinophils for 30 min before migration. The number of migrating eosinophils was determined as described above.
RESULTS
Effect of TBC1269 on the migration of HL-60 -differentiated eosinophils. TBC1269, which acts as a pan-selectin antagonist, resulted in the inhibition of the intestinal epithelial migration of HL-60 -differentiated eosinophils. The effect was dose dependent, and complete inhibition of migration was seen at 10 mg/mL concentration (Fig. 1) . Therefore, the migration of HL-60 -differentiated eosinophils across intestinal epithelial migration seems to be dependent on selectins and/or their ligands. The individual selectins/ligands then were investigated as potential players in the process of migration as described below.
TBC at 10 mg/mL (11 mM) concentration was not found to have any toxic effect on the function or viability of the intestinal epithelial monolayer or the differentiated eosinophils. The following validating experiments were conducted: differentiated eosinophils were incubated with TBC1269 at 10 mg/mL concentration for 30 min, followed by a 150-min incubation in the top reservoir in accordance with the original protocol. The trans-epithelial electrical resistance at the conclusion of the study was measured. The viability of the differentiated eosinophils and T-84 cells, in the presence or absence of TBC1269, was assayed by Trypan blue exclusion. The viability and function of the T-84 cells were comparable to the control cells (viability 88 and 87% for control and TBC, respectively; n ϭ 3; no decrease in TEER was seen in any of the monolayers). The viability of the differentiated eosinophils was similar in the presence or absence of TBC1269 (96 and 97% for control and TBC, respectively; n ϭ 3).
Effect of L-selectin and PSGL-1 blockade on the migration of HL-60 -differentiated eosinophils. Anti-L-selectin MAb was incubated with the HL-60 cells for 30 min before migra- 
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tion. Inhibitory effects were seen at 1 and 10 g/mL, representing an average of 39.2% inhibition when compared with the fMLP-induced positive control. Anti-PSGL-1 MAb was incubated with HL-60 cells for 30 min before migration. Inhibitory effects were seen at 50 and 100 g/mL concentrations, representing an average of 51.6% inhibition (Fig. 2) . When the combination of both blocking antibodies for Lselectin (10 g/mL) and PSGL-1 (100 g/mL) were added to HL-60 eosinophils, the migration process was further inhibited by 76.0% (Fig. 2) .
Effect of TBC1269 on the migration of human peripheral eosinophils. For validating the TBC1269 effect on the migration of the human peripheral eosinophils across a fMLP gradient, TBC1269 was incubated with human peripheral eosinophils before migration into the intestinal epithelial monolayer. TBC1269 inhibited the migration of the eosinophils is a concentration-dependent manner (Fig. 3) .
DISCUSSION
Eosinophils migrate into the intestinal epithelium during several eosinophilic inflammatory conditions (1) . Migration into the epithelium is comparable to the development of eosinophilic cryptitis, whereas migration across the intestinal epithelium is comparable to the development of crypt abscess. Both conditions are the hallmark of a variety of disorders now known as eosinophilic gastrointestinal disorders (11, 12) . Disease development is clearly associated with the migration of eosinophils. Other conditions characterized by the presence of eosinophilic cryptitis and crypt abscess include radiation proctitis, protein-sensitive enteropathy, and helminthic infections (1, (13) (14) (15) . Evidence is mounting to suggest a potential role for eosinophils in inflammatory bowel disease (16 -23) . During the eosinophilic diseases of the intestine, the eosinophils migrate into the intestinal lumen, forming what is known as eosinophilic crypt abscesses (24) . Eosinophil toxic products, such as cationic proteins, oxygen metabolites, proteases, and lipid mediators, are released, which can contribute to epithelial damage (25) .
The infiltration of the leukocytes to the areas of injury and inflammation is accomplished by the coordinated actions of cellular adhesion molecules under the direction of chemokine signaling. A variety of cell adhesion molecules are expressed and used by many leukocytes. Three major groups are involved: selectins, integrins, and the immunoglobulin gene superfamily. P-and E-selectin mediate initial leukocyte adhesion, whereas ␤2-integrin/intercellular adhesion molecule-1 and VLA-4/vascular cellular adhesion molecule-1 (Very Late Antigen) pathways mediate leukocyte arrest and transendothelial migration. The process of eosinophil migration across the endothelium has been widely investigated, yet little is known about eosinophil-epithelial interactions in the gut. Measures that can prevent eosinophil recruitment into and across the intestinal epithelium may have therapeutic value. Primary molecular targets for prevention of eosinophil accumulation are the adhesion molecules that mediate leukocyte interactions with vascular endothelium and extracellular matrix proteins.
However, studies of eosinophil function are hindered by the relative paucity of eosinophils in the circulation and the difficulty in purification from neutrophils. In our studies (26, 27) , 18 -20 million eosinophils are needed to run an individual experiment. Such numbers are difficult to obtain from volunteers. Thus, cell lines that can differentiate into eosinophils present a considerable advantage in large-scale studies for eosinophil chemotaxis. HL-60 is one of several human leukemic cell lines that can be induced to differentiate into cells with histologic, biochemical, and functional characteristics of mature human eosinophils. Specific clones of HL-60, such as clone 15, yield a high concentration of eosinophils when treated with butyric acid (6, 7) . HL-60 cells develop proteins, enzymes, and adhesion molecules characteristic of human eosinophils (28 -30) . They are known to express L-selectin as well (31, 32) .
Integrins that are expressed on eosinophils bind to adhesion receptors that belong to the immunoglobulin superfamily on endothelial cells and are implicated in the subsequent firmer adhesion (33) . Other adhesion molecules that are involved in leukocyte migration include the immunoglobulin superfamily. The three known selectin members are E-selectin, L-selectin, and P-selectin, which are also referred to as CD62 followed by their respective first letters (CD62E, CD62L, and CD62P). E-selectin is expressed on activated endothelium. P-selectin (34), the largest selectin, originally received its name because of its stimulus-dependent expression on platelets, but it is also rapidly and transiently expressed on other cells, such as endothelial cells. L-selectin is the smallest selectin and receives its name because its expression is restricted to leukocytes. Eosinophils constitutively express L-selectin, and they shed it on cell activation (35) . Eosinophils use a functional epitope of Lselectin for ligand binding different from neutrophils (36, 37) . The counterligands for P-selectin on eosinophils is PSGL-1 (38) . sLe x binds to the three known selectins; therefore, compounds that inhibit sLe x act as a selectin antagonist. TBC1269 is a nonoligosaccharide sLe x antagonist and has been shown to block binding to all selectins (39, 40) . In general, eosinophils have been shown in other studies, as well as the current, to require much more TBC1269 to produce an inhibitory effect compared with the neutrophils (40) . In this model of intestinal migration of eosinophils, TBC1269 compound displays potent inhibitory effect, resulting in almost complete abolishment of the migration process. This effect is demonstrated when both HL-60 -differentiated eosinophils and human peripheral eosinophils are used.
The results of this study support a novel function for the selectins. Selectins are traditionally known to be involved in the initial tethering and rolling of leukocytes while the cells are under flow conditions. However, our complete understanding of the selectin role and function is a goal yet to be reached. This study demonstrates a role for the selectins under steadystate conditions and opens avenues to be explored in the future.
TBC1269 selectin antagonism does not distinguish the role of an individual selectin during the process of migration. Therefore, the role of L-selectin and PSGL-1 were individually studied using function-blocking antibodies. Both L-selectin and PSGL-1 play a role during the process of migration. However, blocking their effect still does not result in absolute inhibition of migration as seen with TBC1269. Other carbohydrate-based adhesion molecules or yet-to-be discovered selectins may play a role in the process of migration as well. Overall, the results of this study suggest an important role for selectins in the intestinal epithelial migration of differentiated eosinophils. sLe x , L-selectin, and the P-selectin counterligand PSGL-1 may prove useful as potential therapeutic targets.
